<DOC>
	<DOCNO>NCT00646789</DOCNO>
	<brief_summary>To evaluate safety , tolerability pharmacokinetics ( PK ) MK0633 adolescent mild-to-moderate asthma patient permit clinical investigation .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability Plasma Concentration Profiles MK0633 Asthmatic Children Aged 12 Less Than 16 Years ( 0633-019 )</brief_title>
	<detailed_description />
	<criteria>Patient judge good health , mild moderate asthma , base medical history , physical examination , vital sign , laboratory safety test Patient clinically significant abnormality electrocardiogram ( ECG ) perform prestudy ( screen ) visit and/or prior administration initial dose study drug Patient least 1 year mildtomoderate asthma Patient nonsmoker least 6 month Patients childbearing potential must agree use medically acceptable method contraception study 90 day last dose study drug Patients must able swallow tablet Patient history clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , asthma , genitourinary abnormality diseases Patient require visit hospital emergency room due asthma exacerbation within 3 month prestudy visit Patient unresolved sign symptom upper respiratory tract infection ( URI ) upper respiratory tract infection within 3 week prior prestudy visit Patient history stroke , chronic seizure , major neurological disorder Patient history neoplastic disease Use theophylline , Singulair ( montelukast ) , Xolair ( omalizumab ) , Zyflo amd Zyflo CR ( zileuton ) , oral corticosteroid oral beta agonist exclude approximately 2 week prior administration study drug throughout study Patient consume alcoholic beverage</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>